RxDoctor Payments Data

Michael Sagatelian, MD

Gastroenterology · Charleston, SCNPI 1962452367

Payments from drug & device makers

$9,707in general payments, 2019–2025

Across 498 payments — averaging $19.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Pfizer$620
  • Johnson & Johnson$611
  • QOL Medical, LLC$529
  • Janssen Scientific Affairs, LLC$338
  • plus $4K from 38 others

What the payments were for

  • Consulting fees$150%
  • Food & beverage$9,64399%
  • Education$501%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,707 in reported general payments places this provider in the 70th percentile of 259 gastroenterology providers in South Carolina.

See all gastroenterology providers in South Carolina

Medicare billing

Part B allowed, 2024
$179,631
Medicare patients
614
Services billed
1,341

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XeljanzTofacitinib Citrate20$113,865
LinzessLinaclotide40$30,617
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates227$14,724
Mesalamine19$11,311
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag39$4,832
Colestipol Hcl72$4,521
Esomeprazole Magnesium55$2,994
SutabSod Sulf/Pot Chloride/Mag Sulf18$2,912
Omeprazole192$2,596
Sucralfate11$2,306
Pantoprazole Sodium146$1,843
Dicyclomine Hcl56$974
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl51$846
Ondansetron OdtOndansetron14$487
Metronidazole47$454

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$620$113,86520 claims
AbbVieLinzess$2,682$30,61740 claims
Braintree Laboratories, Inc.Suflave, Sutab$35$7,74457 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 259 gastroenterology providers in South Carolina.

Other gastroenterology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →